Cincinnati Children’s is the second highest recipient of research grants from the National Institutes of Health among pediatric hospitals. Our large research enterprise accounts for a third of our overall operating budget, and a third of our more than 13,000 employees are involved in research.
Within our more than 1 million square feet of research space, scientists conduct basic, translational, clinical and health services research.
The depth and breadth of our research program provides unusual opportunities for trainees in the Israel Exchange Program.
We foster an open environment, encouraging cross-disciplinary collaboration among researchers in all disciplines of medical sciences. The proximity of researchers to clinicians and to a large, well-characterized patient population provides a synergistic environment for research that advances care at the bedside.
Researchers and clinicians at Cincinnati Children’s innovate every day. The Center for Technology Commercialization (CTC) plays a key role in facilitating the translation of discoveries into improved clinical care for children. The CTC is responsible for advancing discoveries from the bench to the bedside.
CTC protects our innovations through patents; assists in further developing technologies through research partnerships; delivers products to the market through licensing and the creation of start-up companies. The CTC also encourages our researchers and clinicians to collaborate and share the results of their work with other institutions through the use of confidentiality agreements and material transfer agreements.
Cincinnati Children’s has a long history of connection with Israel, beginning with Dr. Albert Sabin, who discovered the Sabin oral polio vaccine at Cincinnati Children’s and later became president of Weizmann Institute.
More than 30 Israeli fellows have returned to Israel following training at Cincinnati Children’s, and we are proud to see their continued achievements and leadership roles.